Mississippi's Last Cannabis Labs Merge to Survive Market Correction

FLOWOOD, MS – August 06, 2026 – In a move that underscores the stark economic realities of Mississippi’s nascent medical cannabis industry, the state’s first and last remaining testing laboratories, Steep Hill Mississippi and Alchemy Analytics, have announced a strategic combination. The two entities will now operate under a newly formed holding company, Southern Precision Analytics LLC, in a bid to preserve the state's mandatory testing infrastructure and ensure their own financial survival.

This consolidation is not a typical corporate acquisition but a calculated response to a market that has grown far more slowly than initial forecasts predicted. While the new structure will merge administrative and back-office functions to slash overhead, both Steep Hill and Alchemy Analytics will maintain their individual facilities, scientific teams, and client-facing operations. Allen Whitt, CEO of Steep Hill Mississippi, will lead the new holding company, Southern Precision Analytics.

"This restructuring is about protecting the integrity and continuity of Mississippi's medical cannabis program," Whitt stated in the announcement. "Without this restructuring, neither lab would have the operational scale necessary to remain viable in this market."

A Market Hits the Brakes

The story of this merger is fundamentally a story of market correction. When Mississippi's medical cannabis program launched in January 2023, projections were optimistic, with some anticipating up to 150,000 patient cardholders within a few years. The reality has been more subdued. As of this month, the state has approximately 69,000 active patients, a respectable number but significantly shy of the 100,000-patient benchmark projected for the program’s third year.

This slower-than-expected patient uptake has created a ripple effect across the entire supply chain. The initial boom saw licenses granted for seven testing facilities. However, some never opened, and the market has since winnowed the field down to just two: Steep Hill and Alchemy Analytics. A similar consolidation occurred among dispensaries, which saw their numbers shrink by nearly 15% in 2025 as the market adjusted to actual patient demand.

Several factors contribute to the tempered growth. Industry analysts point to a high patient attrition rate, estimated at 45-50% annually, driven by the cost and administrative hurdles of yearly renewals. Furthermore, Mississippi’s strict regulations, including a near-total ban on advertising, make it difficult for cannabis businesses to reach and educate potential patients, further constraining market expansion.

The High Cost of Confidence

For ancillary businesses like testing labs, the financial pressures have been particularly acute. These facilities are the gatekeepers of patient safety, responsible for conducting the full panel of compliance tests for potency, pesticides, heavy metals, and other contaminants as required by the Mississippi State Department of Health (MSDH). This responsibility comes with immense fixed costs.

Operating a state-of-the-art cannabis lab requires millions of dollars in sophisticated instrumentation, maintaining a stringent ISO/IEC 17025 accreditation, navigating complex regulatory compliance, and retaining a staff of highly skilled chemists and analysts. These costs remain largely the same whether the lab tests ten samples or a thousand, creating a precarious financial model when testing volumes fall short. With patient numbers well below initial projections, the revenue generated from testing simply wasn't enough to support two independent, competing labs.

Whitt’s assessment that neither lab could remain viable alone speaks volumes about the structural challenges. The consolidation under Southern Precision Analytics allows the labs to pool resources for expensive but non-client-facing functions like accounting, human resources, and compliance management, thereby achieving a sustainable operational scale.

Preserving a Pillar of Patient Safety

Leaders of both companies have framed the merger as a proactive and necessary step to protect patients. Without reliable, in-state testing, the entire medical cannabis supply chain would grind to a halt, leaving patients without access to safe, regulated medicine. The strategic decision to keep the laboratories operating as distinct entities is designed to ensure a seamless transition for the cultivators and processors who rely on their services.

"Our clients will keep the lab, the people, and the turnaround times they know," assured Hatem Mourad, MD, CEO of Alchemy Analytics. "Combining back-office operations lets us keep delivering accurate, objective testing across the state."

This structure aims to offer the best of both worlds: the financial stability of a larger, consolidated entity and the operational continuity of the individual labs customers are familiar with. Cultivators and processors will not be forced to change their submission processes or reporting structures, and they can continue to choose which of the two lab locations they prefer. Both facilities will continue to maintain their separate ISO accreditations and full compliance with MSDH regulations.

A New Competitive Landscape

While the merger ensures the survival of critical infrastructure, it fundamentally reshapes the competitive landscape for cannabis testing in Mississippi. The market has effectively transitioned from a field of several potential competitors to a duopoly operating under a single holding company. This concentration raises important questions for the industry's future.

For cultivators and processors, the primary concern is the potential impact on cost and choice. With only two providers, both under the same corporate umbrella, the competitive pressure that helps keep testing prices in check is significantly diminished. While the new entity is focused on survival, the lack of outside competition could lead to higher costs being passed down the supply chain and, ultimately, to patients. Some industry operators privately express concern that a lack of choice could also stifle innovation in testing services over the long term.

Regulators at the MSDH will also face a new dynamic, now overseeing a single, dominant entity rather than a field of competitors. The high barriers to entry—driven by immense capital costs and regulatory hurdles—make it unlikely that a new challenger will enter the Mississippi testing market anytime soon, cementing Southern Precision Analytics’ position. The long-term health of the state's program will depend on this new entity balancing its financial needs with its critical role in providing reliable, accessible, and competitively priced testing for the entire Mississippi medical cannabis industry.